- Home
- SHFS vs LPCN Comparison
SHFS vs LPCN Comparison
Compare SHFS & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHFS
- LPCN
- Stock Information
- Founded
- SHFS 2015
- LPCN 1997
- Country
- SHFS United States
- LPCN United States
- Employees
- SHFS N/A
- LPCN N/A
- Industry
- SHFS Finance: Consumer Services
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- SHFS Finance
- LPCN Health Care
- Exchange
- SHFS Nasdaq
- LPCN Nasdaq
- Market Cap
- SHFS 25.6M
- LPCN 36.8M
- IPO Year
- SHFS N/A
- LPCN N/A
- Fundamental
- Price
- SHFS $0.49
- LPCN $5.46
- Analyst Decision
- SHFS
- LPCN Strong Buy
- Analyst Count
- SHFS 0
- LPCN 1
- Target Price
- SHFS N/A
- LPCN $10.00
- AVG Volume (30 Days)
- SHFS 51.1K
- LPCN 23.4K
- Earning Date
- SHFS 11-12-2024
- LPCN 11-06-2024
- Dividend Yield
- SHFS N/A
- LPCN N/A
- EPS Growth
- SHFS N/A
- LPCN N/A
- EPS
- SHFS 0.08
- LPCN N/A
- Revenue
- SHFS $16,719,536.00
- LPCN $4,800,930.00
- Revenue This Year
- SHFS N/A
- LPCN N/A
- Revenue Next Year
- SHFS N/A
- LPCN N/A
- P/E Ratio
- SHFS $5.56
- LPCN N/A
- Revenue Growth
- SHFS 34.73
- LPCN 8630.55
- 52 Week Low
- SHFS $0.44
- LPCN $2.31
- 52 Week High
- SHFS $1.55
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- SHFS 51.15
- LPCN 61.75
- Support Level
- SHFS $0.46
- LPCN $4.89
- Resistance Level
- SHFS $0.51
- LPCN $5.85
- Average True Range (ATR)
- SHFS 0.03
- LPCN 0.38
- MACD
- SHFS 0.00
- LPCN 0.04
- Stochastic Oscillator
- SHFS 80.61
- LPCN 64.83
About SHFS SHF Holdings Inc.
SHF Holdings Inc is a financial services provider to cannabis-related businesses. It offers reliable access to banking solutions for cannabis, hemp, CBD, and ancillary operators, making communities safer, driving growth in local economies, and fostering long-term partnerships. The group, through its financial institution clients, implements accountability, transparency, monitoring, reporting, and risk mitigation measures while meeting Bank Secrecy Act obligations in line with FinCEN guidance on cannabis-related businesses. Its services include Program Management Support, Customer Generation, Ongoing Program Auditing, and Compliance Monitoring among others.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.